Jaguar Health's Strategic Restructuring Under Scrutiny

First Berlin Equity Research updated its evaluation of Jaguar Health, Inc. Analyst Christian Orquera has placed the company's rating and price target under review. The evaluation highlights Jaguar Health's efforts to restructure its balance sheet since January, including the issuance of Series O preferred stock dividends and amendments to debt agreements.

The company aims to simplify its financial structure, although these steps increase the risk of shareholder dilution. Jaguar Health recently restored its compliance with Nasdaq through a reverse stock split, converted Series O preferred stock into common equity, and established a USD 40 million equity line of credit with C/M Capital to mitigate liquidity risks.

While these moves provide a financing buffer, Jaguar's total notes payable remain a burden given its cash flow situation. Upcoming plans include a Breakthrough Therapy Designation application for crofelemer in MVID, bolstered by favorable feedback from the FDA and ESPGHAN data.